» Authors » Parag H Joshi

Parag H Joshi

Explore the profile of Parag H Joshi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 96
Citations 1526
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Slipczuk L, Kuno T, Marcovina S, Swett K, Orroth K, Lopez J, et al.
JAMA Cardiol . 2025 Jan; 10(2):164-169. PMID: 39745752
Importance: Apolipoprotein B (apoB) distribution and its implications as an atherosclerotic cardiovascular disease (ASCVD) risk-enhancing factor among individuals of diverse Hispanic or Latino backgrounds have not been described. Objective: To...
2.
De Oliveira-Gomes D, Joshi P, Peterson E, Rohatgi A, Khera A, Navar A
Circulation . 2024 Jul; 150(1):62-79. PMID: 38950110
Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical...
3.
Bess C, Mehta A, Joshi P
Prog Cardiovasc Dis . 2024 May; 84:27-33. PMID: 38759878
Lipoprotein(a) [Lp(a)], a genetically determined macromolecular complex, is independently and causally associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis via proposed proinflammatory, prothrombotic, and proatherogenic mechanisms. While Lp(a)...
4.
Parsa S, Saleh A, Raygor V, Hoeting N, Rao A, Navar A, et al.
J Am Coll Cardiol . 2024 Apr; 83(16):1557-1567. PMID: 38631775
Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC...
5.
Pandey A, Patel K, Segar M, Ayers C, Linge J, Leinhard O, et al.
J Cachexia Sarcopenia Muscle . 2024 Apr; 15(3):1072-1083. PMID: 38561962
Background: Excess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat...
6.
Miles J, Scotti A, Castagna F, Kuno T, Leone P, Coisne A, et al.
Circulation . 2023 Nov; 149(6):417-426. PMID: 37970713
Background: Tools for mortality prediction in patients with the severe hypercholesterolemia phenotype (low-density lipoprotein cholesterol ≥190 mg/dL) are limited and restricted to specific racial and ethnic cohorts. We sought to...
7.
Deets A, Joshi P, Chandra A, Singh K, Khera A, Virani S, et al.
J Am Heart Assoc . 2023 Nov; 12(21):e031160. PMID: 37929707
Background High-density lipoprotein (HDL) particle concentration likely outperforms HDL cholesterol in predicting atherosclerotic cardiovascular events. Whether size-based HDL subspecies explain the atheroprotective associations of HDL particle concentration remains unknown. Our...
8.
Joshi P, Marcovina S, Orroth K, Lopez J, Kent S, Kaplan R, et al.
JAMA Cardiol . 2023 May; 8(7):691-696. PMID: 37223894
Importance: Lipoprotein(a) (Lp[a]) is a genetically determined risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD). The Lp(a) distribution among the diverse Hispanic or Latino community residing in the US has not...
9.
Raygor V, Ayers C, Segar M, Agusala K, Khera A, Pandey A, et al.
J Am Heart Assoc . 2023 May; 12(10):e029266. PMID: 37158070
No abstract available.
10.
Kelsey M, Mulder H, Chiswell K, Lampron Z, Nilles E, Kulinski J, et al.
Am J Prev Cardiol . 2023 Apr; 14:100478. PMID: 37025553
Objective: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease, yet little is known about Lp(a) testing patterns in real-world practice. The objective of this analysis was to determine how...